Uncovering nutritional deficiencies and the adequacy of wrap-around care for patients on GLP-1 and dual GIP/GLP-1 receptor agonists
Year: 2026
Type: article
Study design: Observational Study
Abstract: Background Incretin-based therapies, including glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 RAs, are effective treatments for obesity and type 2 diabetes, but little is known about their implications for dietary intake in routine care. Concerns have emerged that appetite suppression may reduce overall food consumption and increase the risk of nutritional inadequacy in the absence of structured dietary monitoring.Methods A mixed methods service evaluation with exploratory analysis was conducted at a single NHS general practice in Northamptonshire, UK. Fourteen adults prescribed incretin-based therapies completed dietary recalls using the validated myfood24 platform and participated in semi-structured telephone interviews. Dietary intake was assessed against UK reference nutrient intakes (%RNI), and interviews were analysed thematically to explore patient experiences of incretin therapy.Results Many participants reported energy intakes below estimated requirements, with three consuming <800 kcal/day. Intakes of several nutrients, particularly fibre, vitamin D and iron, were frequently below recommended thresholds while protein intake generally exceeded requirements. Over half the cohort had multiple nutrients simultaneously below adequacy thresholds. Qualitative findings indicated that medication-related appetite suppression often led to unrecognised reductions in food intake and that participants received limited structured nutritional guidance.Conclusion This exploratory evaluation suggests that some individuals prescribed incretin-based therapies may consume very low-energy diets and fall short of key micronutrient targets despite adequate protein intake. Larger prospective studies are needed to determine the prevalence and clinical implications of dietary inadequacy during incretin therapy and to inform appropriate nutritional monitoring strategies.
Language: English
Subfield: Endocrinology, Diabetes and Metabolism
Field: Medicine
Domain: Health Sciences
Keywords: GLP-1 receptor agonists, GIP/GLP-1 receptor agonist, incretin-based therapy, nutritional deficiency, dietary intake, appetite suppression, micronutrient deficiency, vitamin D, iron, fibers, protein intake, type 2 diabetes, obesity, nutritional monitoring, general practitioner care, patient experience
Open Access status: gold
Estimated APC paid: $1,839
OpenAlex ID: W7125785494
